Janus Henderson Investors, an investment management company, released its “Forty Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. shares increased following positive news about corporate earnings. Economic growth has remained relatively stable despite challenges such as a government shutdown, policy headwinds, and slower-than-expected employment growth. Excitement around artificial intelligence (AI) drove strong returns early in the quarter. However, concerns abo ...

Over the past year, the two leaders in the obesity drug market, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), have lagged broader equities, though the latter has performed substantially worse than the former. Still, analysts predict that this therapeutic area will soar over the next decade, and there is a good chance these two will maintain their edge over their peers given their pipelines. But which one is a better buy? Comparing their weight loss portfolios Eli Lilly's weight loss medicine, Zepbou ...

Phathom's sole commercial asset, VOQUEZNA (vonoprazan), is a potassium-competitive acid blocker approved for GERD and H. pylori treatment. Prescription momentum has been consistent: quarterly fills grew from ~127,000 in Q1 2025 to ~273,000 in Q4 2025, pushing cumulative totals past 1.1 million prescriptions. That commercial traction drove Q4 revenue to $57.58 million, up 94.12% year-over-year, while EPS of -$0.08 significantly beat the -$0.42 consensus estimate. Operating expenses fell to $55.87 million fro ...

Key Takeaways Viking Therapeutics completed enrollment in the phase III VANQUISH-2 study of obesity drug VK2735.The trial targets ~1,000 T2D patients, testing weekly doses with weight loss over 78 weeks as the endpoint.Rapid enrollment and prior data showing up to 14.7% weight loss highlight strong interest in VK2735.Shares of Viking Therapeutics (VKTX) rose more than 3% on Thursday after the company announced that it completed enrollment in the phase III VANQUISH-2 study, which is evaluating the subcutaneo ...

AstraZeneca stock jumps as COPD drug trial win surprises market AstraZeneca stock jumps as COPD drug trial win surprises market Health & pharma AI Sentiment: 82/100 Bullish This score is generated through AI-driven analysis of the article's content. Author Ananthu C U Mar 27, 2026, 14:55 PM Shares of AstraZeneca rose on Friday after the drugmaker reported positive results from late-stage clinical trials of its experimental chronic obstructive pulmonary disease (COPD) treatment, tozorakimab. The UK-based pha ...

NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ: INO). Shareholders who purchased shares of INO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/inovio-pharmaceuticals-inc-loss-submission-form-2/?id=184866&from=3  C ...

NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST). Shareholders who purchased shares of AQST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/aquestive-therapeutics-inc-loss-submission-form/?id=184865&from=3  C ...

After Pfizer's Q4 report ( PFE ), which, as you know, was published on February 3, its stock was up 7%, outperforming the S&P 500 ( SPY ) [-5.7% return]. (These results came in after my last update on Pfizer, which was inWith over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and p ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Iterum files wind-up petition due to limited cash, inability to raise equity | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv March 27 (Reuters) - Iterum Therapeutics (ITRM.O), opens new tabsaid on Friday it has filed a petition in Ireland's High Court to wind up the drugmaker and was placed into provisional liquidation, with a hearing set for April 13. If the court grants a winding-up order, it would lead to an orderly wind-down and eventual dissoluti ...